The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven ...

The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...

Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children ...

Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...

Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has ...

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown ...

Avadel Pharmaceuticals developed Lumryz, a sodium oxybate that is a once ... superstar status and the risks associated with its off-label use. In the age of AI, large data sets – like the ...

The first was a partial legal win against competitor Avadel Pharmaceuticals (AVDL) in late August, where Jazz was not able to get Avadel’s Lumryz off the narcolepsy market, but it was able to ...

Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...